Nature Reviews Urology - Table of Contents alert Volume 13 Issue 11

If you are unable to see the message below, click here to view.

Advertisement
Nature Outlook: Kidney Cancer Kidney cancer has long flown under the radar despite being one of the top-ten cancer killers worldwide. It remains hard to detect, difficult to treat and poorly understood. But that is starting to change as researchers dig into the mysteries surrounding the disease.  Access the Outlook free online for six months  Produced with support from: Eisai Inc.
TABLE OF CONTENTS
November 2016 Volume 13 Number 11		Advertisement
2015 2-year Impact Factor 5.957 Journal Metrics 2-year Median 4	In this issue Research Highlights News and Views Reviews Perspectives Correction Also this month  Featured article: An update on focal therapy for prostate cancer Marlon Perera, Nishanth Krishnananthan, Uri Lindner & Nathan Lawrentschuk	The Naturejobs Career Expo is returning to Düsseldorf. Friday 18, November 2016 This free career fair offers talented scientists an excellent opportunity to meet a diverse selection of national and international employers from academic institutions and scientific industries, such as pharmaceutical organisations, digital technology companies, science publishing and much more.  Register free today!
Subscribe   Facebook   RSS   Recommend to library   Twitter
RESEARCH HIGHLIGHTS Top Kidney cancer: HIF-2α — a new target in RCC Published online: 27 September 2016 p627 | doi:10.1038/nrurol.2016.184 PDF Kidney cancer: Papillary features predict survival in ncRCC Published online: 20 September 2016 p628 | doi:10.1038/nrurol.2016.186 PDF Regenerative medicine: Isolation of nephron progenitors: a step towards growing kidneys? Published online: 04 October 2016 p628 | doi:10.1038/nrurol.2016.196 PDF Prostate cancer: Non-traditional CTCs indicate prognosis Published online: 07 September 2016 p629 | doi:10.1038/nrurol.2016.174 PDF Testicular cancer: Genetic determinants of cisplatin resistance Published online: 04 October 2016 p629 | doi:10.1038/nrurol.2016.197 PDF Kidney cancer: DA transporter a ccRCC biomarker? Published online: 11 October 2016 p629 | doi:10.1038/nrurol.2016.198 PDF Bladder cancer: Rho-sensitive pathway mediates metastasis Published online: 27 September 2016 p630 | doi:10.1038/nrurol.2016.192 PDF Kidney cancer: On target — inhibiting SPOP in ccRCC Published online: 04 October 2016 p630 | doi:10.1038/nrurol.2016.195 PDF BPH: Disrupting AR signalling promotes inflammation Published online: 27 September 2016 p631 | doi:10.1038/nrurol.2016.187 PDF Prostate cancer: Targeting apoptosis resistance in CRPC Published online: 11 October 2016 p631 | doi:10.1038/nrurol.2016.200 PDF Prostate cancer: HSD3B1 variant confers inferior ADT outcomes Published online: 20 September 2016 p632 | doi:10.1038/nrurol.2016.183 PDF IN BRIEF Kidney cancer: Micrometastases detectable using flow cytometry | Urinary incontinence: Use of α-blockers plus desmopressin is safe | Testicular cancer: Radiotherapy increases pancreatic cancer risk | Prostate cancer: Circulating miRNAs indicate high-risk disease PDF
NEWS AND VIEWS		Top
Prostate cancer: Active surveillance appropriateness criteria — a way forward Svetlana Avulova & Daniel A. Barocas Published online: 31 October 2016 p633 | doi:10.1038/nrurol.2016.202 A newly published report, indicating a high level of use of active surveillance (AS) is encouraging; however, the substantial variability in levels of implementation indicate that some urologists remain uncertain of this approach. This report encourages the standardized implementation of AS and improved counselling of patients that are eligible for such monitoring. Full Text | PDF
Prostate cancer: Estimated life expectancy: integration of age and comorbidities Axel Heidenreich & David Pfister Published online: 18 October 2016 p634 | doi:10.1038/nrurol.2016.203 Most guidelines recommend integration of estimated life expectancy into the routine decision-making process in prostate cancer treatment. This article underlines the use of both age and comorbidities to calculate life expectancy, which is highly dependent on the health status of the individual patient. Full Text | PDF
Prostate cancer: Kinases and CHIPS sign-off personalization of therapy Natasha Kyprianou Published online: 11 October 2016 p636 | doi:10.1038/nrurol.2016.194 A recent study in Cell undertook a bold phosphoproteomic data interpretation and functional integration approach to develop a clinically relevant hierarchy of therapeutic kinase targets and actionable pathways of individual patients with metastatic castration-resistant prostate cancer. Each patient's personalized kinase signature can be used to guide clinical decisions and predict drug combinations, minimizing toxicity and optimizing precision-targeted treatment. Full Text | PDF
Penile cancer: Welcome changes in disease management and remaining challenges Ben Ayres & Nick Watkin Published online: 31 October 2016 p637 | doi:10.1038/nrurol.2016.204 Achieving the best possible practice in the management of patients with penile cancer is hampered by a lack of evidence owing to the rare occurrence of this disease. New population-based data from the USA show improved surgical and medical practice patterns but also highlight challenges in providing optimum care to all patients. Full Text | PDF
Prostate cancer: What is the optimal treatment sequence for mCRPC? Oliver Sartor Published online: 31 October 2016 p639 | doi:10.1038/nrurol.2016.205 Now that patients with metastatic castration-resistant prostate cancer have multiple therapeutic options, the question naturally arises as to how these therapies should be sequenced. The genitourinary group at Johns Hopkins has attempted to answer this question by investigating abiraterone and enzalutamide sequencing information in their database. Full Text | PDF
Advertisement
Covering the evolution of science since 1869, Nature has a multidisciplinary global scientific network of readers. Join a community of great minds and be part of the discussion with a personal subscription from £65 (UK), $93 (US), €84 (EU).
REVIEWS		Top
An update on focal therapy for prostate cancer Marlon Perera, Nishanth Krishnananthan, Uri Lindner & Nathan Lawrentschuk Published online: 27 September 2016 p641 | doi:10.1038/nrurol.2016.177 Focal therapy is an emerging treatment option that involves the focal ablation of prostate cancer with preservation of surrounding healthy tissue, which might result in reduced morbidity. In this Review the authors discuss the controversy surrounding optimal patient selection, preoperative tumour localization strategies and the lack of long-term oncological data for focal therapy modalities. Abstract | Full Text | PDF | Supplementary information
An overview of kidney stone imaging techniques Wayne Brisbane, Michael R. Bailey & Mathew D. Sorensen Published online: 31 August 2016 p654 | doi:10.1038/nrurol.2016.154 Imaging is an important diagnostic tool and initial step in deciding which therapeutic options to use for the management of kidney stones and guidelines differ regarding the optimal initial imaging modality. In this Review, Brisbane and colleagues discuss the advantages and disadvantages of CT, ultrasonography, MRI and kidney, ureter, bladder (KUB) plain film radiography for stone imaging and propose an algorithm for imaging patients with acute stones. Abstract | Full Text | PDF
Management of stage I testicular germ cell tumours Michal Chovanec, Nasser Hanna, K. Clint Cary, Lawrence Einhorn & Costantine Albany Published online: 13 September 2016 p663 | doi:10.1038/nrurol.2016.164 Care must be taken to limit the long-term risks of treatment of stage I testicular germ cell tumours (TGCT) as long-term survival is [sim]99%. The management of this disease remains controversial as the options are to overtreat to prevent relapse, or to observe and treat only patients who experience disease relapse. In this Review, Chovanec and colleagues discuss the options for the management of clinical stage I TGCT. Abstract | Full Text | PDF
Zero ischaemia partial nephrectomy: a call for standardized nomenclature and functional outcomes Ahmad Alenezi, Giacomo Novara, Alexander Mottrie, Salah Al-Buheissi & Omer Karim Published online: 18 October 2016 p674 | doi:10.1038/nrurol.2016.185 The introduction of partial nephrectomy for the removal of small renal masses has enabled preservation of patients' renal function. However, this technique involves clamping of the renal hilum, resulting in ischaemia. In the past 5 years, researchers have developed a variety of techniques described as 'zero ischaemia'. Here the authors describe these various techniques and their outcomes, highlighting a need for standardized nomenclature and outcome measures. Abstract | Full Text | PDF
PERSPECTIVES		Top
OPINION A new era of Asian urology: a SWOT analysis Rajeev Kumar Published online: 23 August 2016 p685 | doi:10.1038/nrurol.2016.153 Asia is an emerging centre of growth in the field of urology owing to large and varied patient populations, the availability of a trained workforce, the use of English as a common language, and overall low costs. Asian urology has immense potential to expand in areas in which it currently lags behind, especially research. In this Perspective, Kumar uses a strength-weakness-opportunities-threats (SWOT) analysis to discuss the current state of urology in Asia and comment on the future direction of this field in this region. Abstract | Full Text | PDF
CORRECTION		Top
Correction: In a spin — disorientated divisions disrupt germ cells Louise Stone Published online: 31 October 2016 p689 | doi:10.1038/nrurol.2016.211 Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Nature Reviews Urology was previously published as Nature Clinical Practice Urology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.